Will #PAD4 levels predict pts w #CCP positive #arthralgia who will develop #RA? Leeds study - 79 at risk pts PAD4 levels may predicting #rheumatoid #arthritis development #ACR25 @RheumNow @ACRheum abst#832 https://t.co/dnAA6z3NJQ

• https://x.com/Janetbirdope/status/1983653505908015460/photo/1

Meta analysis evaluating age specific incidence across multiple registries (n=882) Incidence 9.3 for women & 1.4 for men per 100k person-years 1. Wider distribution than I would have guessed 2. Much less age-dependency for men @RheumNow #ACR25 Abstr#29W06 https://t.co/46dNGBZ45V

• https://x.com/EBRheum/status/1983645171914064370/photo/1
• https://x.com/EBRheum/status/1983645171914064370/photo/1
• https://x.com/EBRheum/status/1983645171914064370/photo/1

Phase 1 study of CAR-Treg in difficult to treat RA 4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required & good prelim safety data CAR-T remains exciting, but less of the "totally magical everyone cured" stuff we saw w/initial CAR-T reports @RheumNow #ACR25 https://t.co/kjBIkLCYpF

• https://x.com/EBRheum/status/1983643165383889329/photo/1
• https://x.com/EBRheum/status/1983643165383889329/photo/1
• https://x.com/EBRheum/status/1983643165383889329/photo/1
• https://x.com/EBRheum/status/1983643165383889329/photo/1

"Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD" - Gregory McDermott (Epi Abstracts, #2662) Totally agree with this! SARD guidelines recommendingn drugs with mediocre activity in RA was surprising @RheumNow

Excited about this target trial emulation in RA-ILD Compared to RTX, NO significant difference in hospitalization/transplant/death for JAK, ABA, IL6 or TNF Trends toward ABA and JAK looking better than RTX Need trials for sure, but I like this project a lot @RheumNow #ACR25 https://t.co/FQcphRvyHK

• https://x.com/EBRheum/status/1983640034642108454/photo/1
• https://x.com/EBRheum/status/1983640034642108454/photo/1
• https://x.com/EBRheum/status/1983640034642108454/photo/1

#2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & microstructure, worsening with disease activity. TNFi, RTX & BARI improved MCP bone density, highlighting the impact of inflammation and treatment. @RheumNow #ACR25

Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis? Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate Improvemt in #clinical #disease #activity less inflammation on #synovial #biopsies 3 pts #LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx

• https://x.com/Janetbirdope/status/1983600216126431595/photo/1

GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX 🔹 Lower incidence of OA, RA & gout w/ GLP-1 RA 🔹 No significant differences for PsA, SSc, axSpA, or SLE @RheumNow #ACR25 https://t.co/BIVw3ajrFZ

• https://x.com/AkhilSoodMD/status/1983599716341575701/photo/1

#2662 Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi No sig differences in mortality, resp, hospitalisation or lung transplant across groups, suggesting other b/tsDMARDs may be as safe as RTX for RAILD @RheumNow #ACR25

Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon? Log₂NLR significantly correlated with all three IFN signatures across patients with SLE, systemic sclerosis, rheumatoid arthritis, and myositis @RheumNow #ACR25 https://t.co/ujaOQGvAUV

• https://x.com/AkhilSoodMD/status/1983594626222354713/photo/1

McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen in hospitalisation or death. Trends to abatacept and JAKi looking better... @RheumNow #ACR25 Abstr#2662 #ACRBest https://t.co/ghHEKztvgz

• https://x.com/RichardPAConway/status/1983593423803154669/photo/1

#PD1 Ab looks good and safe in active RA Rosnilimab, a Selective and Potent Depleter of Pathogenic T Many failed several Rx already No safety signals compared to another PD1i Proof of benefit in biospecimens too! abst#LB19 #ACR25 @RheumNow @ACRheum #ACRBest https://t.co/TmEOCfuHZU

• https://x.com/Janetbirdope/status/1983592114001998194/photo/1
• https://x.com/Janetbirdope/status/1983592114001998194/photo/1

#2661 In >5000 veterans with RA-ILD, 8 distinct FVC trajectories were identified. >1/2showed a progressive decline (≥0.7%/yr). These progressive patterns predicted higher mortality & respiratory hospitalisations, underscoring major disease heterogeneity. @RheumNow #ACR25